2Lembuis.T,Wellss,Seheffold,et al.Autologous cytokine-induced killer cells for treatment of rllapsed Hodgkin s disease and non-Hodgkin's lymphoma.Blood,2000;96:839a.
3Elmmaagacli AH,Beelem DW,et al.A retrospective single centre study of the outcome of five different after allogeneic bone marrow transplation.BMT,1997;20:1045-1055.
5Schmid C,Labopin M,Nagler A,et al:Donor lymphocyte infusion in The treatment of first hematological relapse after allogeneic stem cell Transplantation in adults with acute myeloid leukrnia:A retrospective Risk factors analysis and comparison with other strategies by the EBMT leukemia working party.J.Clinical Oncol,2007:25(31):4939-4945.
6SakaiM,ohashi.K,et al.Cytogenetic abnormalities without evidence of relapse after treatment with imatimib and stem cell transplantion in a patient with Ph-postive All.Int.J.Hematol,2005;81:171-173.
7Agis H,Mannhalter C,Sperr WR,et al.Detection of trisomy 8 in donor ph+ cells in a patient with ph+ chronic myeloid leukemia in successfully treated with Imatimib in relapse after allogeneic transplantation.Leuk Lymphoma,2004;45:1453-1458.
8Yoshimitsum M,Fujiwara H,Ozaki A,et al.Case of a patient with phiadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloabative allogeneic hematopoietic srem cell transplantion treated successfully with imatinib and sequential donoe lymphocyte infusions.Int.J.Hematol,2008;88:331-335.
2Marmont A, Frassoni F, Bacigalupo A, et al. Recurrence of Ph-positive leukemia in donor cells after marrow transplantation for chronic granulocvtic leukemia. N Engl J Med, 1984,310:903-906.
3Elmaagacli AH, Beelen DW, Schaefer UW. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transolantation. Bone Marrow Transplant, 1997,20 : 1045-1055.
4Prinz E, Keil F, Kalhs P, et al. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation. Ann Hematol,2003 ,82 :295-298.
5Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant ,2004,10 : 195-203.
6Choi SJ ,Lee J-H ,Lee JH ,et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion:a high incidence of isolated extramedullary relapse. Leukemia,2004,18 : 1789-1797.
7Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.Cancer Control,2002,9:123-137.
8Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood,2000,95:67-71.
9Leis J, Porter DL. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation. Leuk Lymphoma,2002,43:9-17.
10Porter DL, Collins RH Jr, Hardy C, et al. Treatment of replased leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood ,2000,95 : 1214-1221.
同被引文献23
1Arellano ML, Langston A, Winton E, et al. Treatment ofrelapsed acute leukemia after allogeneic transplantation.. A singlecenter experience. Biol Blood and Marrow Transplant, 2007,13(1):116-123.
2Introna M, Franceschetti M, Ciocca A, et al. Rapid and massiveexpansion of cord blood-derived cytokine-induced killer cells: Aninnovative proposal for the treatment of leukemia relapse aftercord blood transplantation. Bone Marrow Transplant, 2006, 38(9):621-627.
3GIuckman E, Broxmeyer HA, Auerbah AD, et al.Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engi J Med, 1989,321(17) :1174-1178.
4Gluckman E, Rocha V. Cord blood transplantation: state of the art. Haematologica, 2009,94(4) :451-454.
5Stanevsky A, Goldstein G, Nagler A. Umbilical cord blood transplantation: Pros, cons and beyond. Blood Rev, 2009,23 (5) : 199-204.
6Gratwohl A, Brand R, Apperley J, et al. Allogeneichematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation(EBMT). Haematologiea, 2006,91 (4) : 513-521.
7Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood, 2009, 114(19): 4293-4299.
8MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant, 2008, 14(9 Suppl):16-22.
9Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep, 2010,5(3):157-162.
10AldersonRF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immuno- therapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res, 2009, 15(3) :832-839.
